Advertisement

Mauna Kea Technologies receives regulatory approval in China for its Cellvizio confocal endomicroscopy device and lands a partnership with Fujifilm China to develop the market there.

Mauna Kea Technologies logo

The China State Food & Drug Administration approved Mauna Kea Technologies' Cellvizio confocal endomicroscopy system, a device design to see cancer faster.

Mauna Kea Technologies launched a strategic partnership with Fujifilm Holdings (TSE:4901) subsidiary Fujifilm China Investment Co., Ltd., to develop its optical biopsy market throughout China in various indications, according to the press release.

Advertisement
Advertisement